Perindopril in Heart Failure with Reduced Ejection Fraction - A Clinical Case
DOI:
https://doi.org/10.52340/spectri.2024.10.01.18Keywords:
heart failure, reduced ejection fraction, perindoprilAbstract
This clinical case describes a 57-year-old male patient diagnosed with heart failure with reduced ejection fraction (HFrEF), atrial fibrillation, and coronary artery disease. Based on the patient’s clinical presentation, laboratory and imaging data, a complex diagnosis was established. Management included inpatient stabilization, coronary stenting, electrical cardioversion, and a multi-drug regimen aligned with current international guidelines. The treatment resulted in significant clinical and echocardiographic improvement. Special emphasis was placed on the use of perindopril as an inhibitor of the renin–angiotensin–aldosterone system (RAAS). This case underscores the importance of personalized, evidence-based strategies and perindopril role in the management of heart failure.
Bottom of Form
Downloads
References
Seferović, P. M., Vardas, P., Jankowska, E. A., Maggioni, A. P., Timmis, A., Milinković, I., ... & Voronkov, L. The heart failure association atlas: heart failure epidemiology and management statistics 2019. European journal of heart failure, 2021; 23(6): 906-914.
Maddox TM, Januzzi Jr JL, Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2024 Apr 16;83(15):1444-88.
Authors/Task Force Members, McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European heart journal. 2012 Jul 1;33(14):1787-847..
Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Current Heart Failure Reports. 2004 Jun;1(2):45-50.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 May 3;79(17):e263-421.
Dunlay, S. M., Roger, V. L., & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 2017;14(10): 591-602.
Savarese G, Lund LH. Global public health burden of heart failure. Cardiac failure review. 2017 Apr;3(1):7.
Patel, A. (2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet, 370(9590), 829-840.
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., ... & Östergren, J. . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet, 2005;366(9489): 895-906.
European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet, 2003;362(9386): 782-788.
Chapman, N., Huxley, R., Anderson, C., Bousser, M. G., Chalmers, J., Colman, S., Woodward, M. Effects of a perindopril-based blood pressure–lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke, 35(1), 116-121.
Curran, M. P., McCormack, P. L., & Simpson, D. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease. Drugs, 2006; 66: 235-255.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
